文献速递病毒性肝炎细菌感染、耐药与抗菌药物

纽约市阿片类使用障碍药物辅助治疗队列中丙型肝炎病毒发病率

Hepatitis C Virus Incidence in a Cohort in Medication-Assisted Treatment for Opioid Use Disorder in New York City.
PubMed 文献 · J Infect Dis · 2020-01-01

该研究在纽约市一个药物辅助治疗(MAT)项目中直接测量了2013至2016年丙型肝炎病毒(HCV)的发病率,并分析了HCV社区病毒载量(CVL)的地理分布及其与发病率的关系。在8352例患者中,HCV患病率为48.7%;在2535例首次抗体检测阴性的患者中,发病率为2.25/100人年,注射用药者达6.70/100人年。女性、注射用药和MAT保留率较低与发病率升高相关,而较高美沙酮剂量与较长的血清阳转时间相关。

要点

  • 注射用药者HCV发病率显著高于总体人群。
  • 女性、注射用药及MAT保留率低与HCV发病率升高相关。
  • 美沙酮剂量<60 mg与更短的HCV血清阳转时间独立相关。

核心结论

  • HCV发病率在MAT保留率较低者中较高,在较高美沙酮剂量者中较低。
  • HCV社区病毒载量存在地理差异,值得进一步研究作为HCV发病率的预测因素。

研究设计与样本

  • 直接测量HCV发病率,并计算区域层面的HCV社区病毒载量。

主要发现

  • 8352例患者中HCV患病率为48.7%。
  • 2535例首次抗体检测阴性的患者中,HCV发病率为2.25/100人年(PYO)。
  • 报告主要用药方式为注射者中发病率达6.70/100 PYO。
  • 女性、注射用药和MAT保留率较低与更高的发病率比率显著相关。
  • 女性、注射用药和美沙酮剂量<60 mg与更短的HCV血清阳转时间独立相关。

关键数值与推荐

  • HCV发病率总体为2.25/100 PYO,注射用药者中为6.70/100 PYO。
  • 美沙酮剂量<60 mg与更短的HCV血清阳转时间独立相关。

临床怎么用

  • 应确保MAT的高保留率和充足的美沙酮剂量。
  • 需加强HCV预防和治疗参与。
  • 关注HCV社区病毒载量的地理差异,作为潜在发病率预测指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hepatitis C virus (HCV) incidence has increased in the worsening opioid epidemic. We examined the HCV preventive efficacy of medication-assisted treatment (MAT), and geographic variation in HCV community viral load (CVL) and its association with HCV incidence. METHODS: HCV incidence was directly measured in an open cohort of patients in a MAT program in New York City between 1 January 2013 and 31 December 2016. Area-level HCV CVL was calculated. Associations of individual-level factors, and of HCV CVL, with HCV incidence were examined in separate analyses. RESULTS: Among 8352 patients, HCV prevalence was 48.7%. Among 2535 patients seronegative at first antibody test, HCV incidence was 2.25/100 person-years of observation (PYO). Incidence was 6.70/100 PYO among those reporting main drug use by injection. Female gender, drug injection, and lower MAT retention were significantly associated with higher incidence rate ratios. Female gender, drug injection, and methadone doses <60 mg were independently associated with shorter time to HCV seroconversion. HCV CVLs varied significantly by geographic area. CONCLUSIONS: HCV incidence was higher among those with lower MAT retention and was lower among those receiving higher methadone doses, suggesting the need to ensure high MAT retention, adequate doses, and increased HCV prevention and treatment engagement. HCV CVLs vary geographically and merit further study as predictors of HCV incidence.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Jordan AE, Cleland CM, Wyka K, et al. Hepatitis C Virus Incidence in a Cohort in Medication-Assisted Treatment for Opioid Use Disorder in New York City. J Infect Dis. 2020. PMID: 32877567. doi:10.1093/infdis/jiz659

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。